UNVC yields 80000.00% · ABBV yields 3.06%● Live data
📍 UNVC pulled ahead of the other in Year 1
Combined, UNVC + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of UNVC + ABBV for your $10,000?
Univec, Inc., through its subsidiaries, produces, licenses, and markets medical products in the United States and internationally. It primarily provides auto-disable and safety syringes. The company offers 1 cc AD-syringe for aspirating and non-aspirating applications, which are used for dispensing dosages of allergy, immunization, and insulin medicines. It also manufactures and markets sliding sheath syringes that are designed to protect patients and healthcare workers from needle stick injuries; and bifurcated needle safety syringes, which are used in administering smallpox vaccines in response to bio-terrorist threats. Univec markets its auto-disable syringes and sliding sheath safety syringes to private hospitals, health facilities, and distributors in the United States, as well as to governments of developing countries. In addition, it assists pharmaceutical companies in marketing, fulfillment, and tracking drug samples via an online system connecting pharmacies and managed payment providers. The company was founded in 1992 and is based in Baltimore, Maryland.
Full UNVC Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.